RxCalc
59
Quality Score
Solid
RxCalc
Low confidence
✍️ bumetric analysis
“
RxCalc is an iOS app from Rob Fahrni in the Education category, currently rated 4.6★ across 5 ratings. Initial signal reads as largely positive sentiment, users highlighting consistency and feature depth.
Quality Score is 59: Solid (established niche player). For a Education app, that means established niche player. The full BU Investment Matrix below scores 8 dimensions including monetisation, growth, and operational risk.
Track changes month-over-month in the Performance section below: live snapshot history and revenue forecast included.
💰 Monthly revenue · now vs forecast
● Right now
$1.3K
per month
→
12-mo forecast
$1.2K – $4.2K
per month
→
24-mo forecast
$1.1K – $9.7K
per month
INDIE tier
💡 Grow this revenue
Free AI audit of this app’s store listing
- Title & subtitle keyword fit
- Description hook & conversion structure
- Screenshots, ratings, reviews strategy
Typical impact: +2-5× organic installs
📊 Performance Tracking LIVE
Loading…
Rating
—
Reviews
—
Forecast Revenue / mo
—
Snapshots tracked
0
since first record
ONE-TIME · BUILD
💰 Estimated build cost
$60K
↳ What it cost to build · not monthly revenue
Likely range $45K – $80K
$25K · MVP floor
$100K · indie scale
$500K+ · studio build
📈
Pays back in ~3 months at current MRR
Synthetic estimate. Inputs: category complexity, file size, screen count, monetization layer, platform reach, age × team-size proxy. Calibrated against 2024-2026 indie-agency rate surveys. Full math + source list on /methodology.
Where the money goes
| 🧱 MVP baseline (design + 1-store ship) | +$28K |
| 📱 5 unique screens × $4.5K | +$22K |
| ⚙ Education complexity ×1.20 | +$10K |
Total estimate
$60K
ONE-TIME · EXIT VALUE
💵 Estimated acquisition value
$300K
↳ What it would sell for · not monthly revenue
Marketplace range $225K – $375K · 16× MRR multiple
💸
~5.0× return on build cost
Synthetic estimate. Multiple band derived from ad-supported + age, rating quality, category demand, and user-base maturity. Calibrated against 2024-2026 indie-app-marketplace closed-deal medians. Full math + comparable deal list on /methodology.
How the multiple was built
| 📺 Ad-supported base | 15× MRR |
| ⭐ ★ rating ≥ 4.4 (solid) | +8% |
| 🏷 Education category multiple | +6% |
| ⭐ Small user base (<1K ratings) | -8% |
Final multiple
16× MRR
🔬
How we forecast this revenue
MEDIUM CONFIDENCEBaseline
$1.3K/mo · ML-estimated from 234 triggers
Growth rate
+6.0% MoM · INDIE tier baseline (compound monthly)
Direction
Headwinds: rating drift may slow acquisition
6 months
$1.1K – $2.6K
12 months
$1.2K – $4.2K
24 months
$1.1K – $9.7K
Compound growth at +6.0% MoM (tier baseline for INDIE). Range widens with horizon — typical noise band ±40% at 6mo.. Ranges widen with horizon — distant futures carry more uncertainty.
📊
BU Investment Matrix
Pre-traction · 39/100INDIE TIERlimited signalGrowth Velocity
5.0
Founder Strength
5.3
Product Quality
3.7
Revenue Strength
3.1
Monetization Maturity
1.0
Defensibility
4.5
Market Position
2.0
Operational Safety
7.0
- 💰 Revenue: Modest — $530 - $3315/mo · INDIE tier · medium confidence, trajectory unclear.
- ⭐ Quality: 4.6★ across 5 reviews — weak — significant quality concerns.
- 📍 Market: Not yet charting in any of the 9 monitored markets.
- 📈 Growth: ⚠ last update 780d ago — possibly dormant.
- ⚠️ Risk: Moderate — dormant (780d since update).
🎯 For competitors: Mixed picture. Worth competing if you have a clear UX or pricing edge — otherwise crowded segment.
💵 For acquirers: Estimated asking range 18-32× monthly = $23K-$42K. Portfolio play ($18K/mo combined) commands premium.
Composite of 8 dimensions computed deterministically from public signals — no LLM, every score traces back to a measurable input. Default weights shown; "compete" / "acquire" / "invest" lenses re-weight without re-fetching.
Range:
💰 Forecast Revenue / mo
MODELRevenue forecast computed from BU's 234 trigger model on each snapshot. Calibrated against ground-truth from 58 verified-revenue apps.
🔬Forecast Breakdown — Why This Estimate?Top 7 of 7 triggers
Our ML model uses 200+ signals from public data. These are the most influential for this app:
| Paid app ($2.99)METRIC | +$2,800 | |
| Excellent rating (4.6★)METRIC | +$2,200 | |
| 5 starREVIEW | +$1,800 | |
| Mature app (16y old)METRIC | +$1,500 | |
| highly recommendREVIEW | +$1,400 | |
| Single-language (English only)METRIC | −$400 | |
| Pre-traction phase (5 ratings)METRIC | −$300 |
METRIC = structural app data · REVIEW = mined from user reviews · ✓ VERIFIED = Stripe-verified anchor (TrustMRR)
📈 Reviews Growth
LIVECumulative review count from first BU snapshot. Each point = a tracked update.
⭐ Rating Trend
LIVEAverage rating evolution. Updates with each new review batch.
🆕 What's New · v1.6
Set minimum iOS version to 15.0
Profile & Insights
Everything we know — and don't — about this app and its company.
Identification
- App name
- RxCalc
- Developer
- Rob Fahrni
- Bundle ID
- com.applecorelabs.RxCalc
- App Store URL
- Open in App Store
- Category
- Education
- Content rating
- 12+
- Languages
- EN
Company
- Website
- Not found
- Tagline
- RxCalc
- Description
- Not found
- Founded
- Not found
- HQ / Address
- Not found
- Employees
- Not found
- Logo
- Not found
Revenue
- Verified revenue / mo
- Not found
- AI revenue estimate / mo
- Not found
- AI annual estimate
- Not found
- ML model estimate / mo
- $18.5K/mo
- Top-grossing rank
- Outside top 100 in US Education
- All-time revenue
- Not found
- Pricing
- Not found
Founder
Founder data not yet collected for this app.
Funding
Funding data not yet collected for this app.
Press & Links
Press & Links data not yet collected for this app.
Contacts & Socials
Contacts & Socials data not yet collected for this app.
⭐Recent App Store Reviews14 latest · avg 3.21★ · 42.9% 5★ · 35.7% 1★
5★6 (43%)
4★1 (7%)
3★2 (14%)
2★0 (0%)
1★5 (36%)
+0 ratings/week
Praise: great ×4 recommend ×2 love ×1
Top positive
★★★★★ Love it
I like this app it's simple and to the points. Pretty handy when your on the floor. You don't have too many options to confuse you but you can still adjust VD to your liking. I'm surprised this app is not reviewed or used tha…
★★★★★ Very helpful
This has been the most useful app for doing pharmacokinetics that I found. It does the calculations for aminoglycosides, vancomycin and high dose extended interval dosing. I have been using it for over five years. It's efficient, no fr…
Top negative
★☆☆☆☆ RxCalc
I have been a clinical pharmacist for 19-years. For the last 8-10 years, I have been using ClinRx on my palm. Unfortunately, ClinRx is not available for I-Pod/I-Phone. I misplaced my palm and was looking for an alternate program. I had …
★☆☆☆☆ Needs transparency
Like others I found this program to significantly underdose patients. The Ke value calculated to about half that of accepted methods. The equation for Ke should be made transparent. The program should also offer multiple methods of kinetic …
📈Ratings growth5 ratings+400% lifetimeShow 3-year history estimate ▾
Tracked (17 weeks) Pre-tracking estimate (37 weeks) · model-based, ±5% noise · anchored to release date and current value
🌍Geographic ReachNot ranked
This app is currently outside the top 100 grossing in all 9 countries we monitor (US, UK, DE, FR, JP, CA, AU, BR, IN). Niche or new apps often launch this way — popularity rankings appear once daily revenue clears the regional threshold.
Profile is built from iTunes Lookup + developer site scrape + ML revenue model. Empty fields show "Not found" — additional sources (Crunchbase, X, IndieHackers, Acquire.com) coming.
📝 About this app
RxCalc puts commonly used pharmacokinetic calculations in the palm of your hand with your iPhone or iPod Touch. The fast interface and comprehensive results help you spend less time crunching numbers and more time working on other, more important issues.
This tool is designed to help pharmacists, and physicians, quickly perform the most commonly used pharmacokinetic calculations. Calculations for designing new vancomycin and aminoglycoside dosing regimens as well as patient specific post-level adjustments to current dosing regimens are included.
This tool is designed to help pharmacists, and physicians, quickly perform the most commonly used pharmacokinetic calculations. Calculations for designing new vancomycin and aminoglycoside dosing regimens as well as patient specific post-level adjustments to current dosing regimens are included.
App Specs
🔐 Own this app? Claim & verify MRR →💾 1 MB🔞 12+📱 iOS 15.0+🔖 v1.6🔄 updated 0d ago🌐 EN📂 Education💰 Paid
📅
What Worked™ · Development Pipeline
8 EVENTS TRACKEDDetected changes in this app over its tracked lifetime — each event links cause (what changed) to effect (what moved). Sorted newest first.See full history →Version history →
2026-03
⭐
Rating ↑ 3.33 → 4.60 (improved 1.27★)
2026-03
💲
Went paid — introduced $2.99 price point
2011-01
📈
Crossed 10 ratings — social-proof flywheel kicking in
2010-08
⭐
Rating ↓ 3.50 → 3.14 (dropped 0.36★)
2010-02
⭐
Rating ↓ 4.00 → 3.50 (dropped 0.50★)
2010-01
⭐
Rating ↓ 4.67 → 3.75 (dropped 0.92★)
2009-08
⭐
Rating ↓ 5.00 → 4.50 (dropped 0.50★)
2009-07
🚀
First tracked snapshot — initial data captured
🌍
Multi-Country Performance
Available in 7 of 9 monitored markets| Market | Rating | Reviews | Current version |
|---|---|---|---|
| 🇦🇺 AU | 2★ | 3 | 2★ this version |
| 🇧🇷 BR | 0★ | 0 | — |
| 🇨🇦 CA | 2★ | 3 | 2★ this version |
| 🇬🇧 GB | 3★ | 4 | 3★ this version |
| 🇮🇳 IN | 0★ | 0 | — |
| 🇯🇵 JP | 3.66667★ | 3 | 3.66667★ this version |
| 🇺🇸 US | 4.59999★ | 5 | 4.59999★ this version |
🔔
Track this app’s revenue
FREEGet an email when revenue moves by your threshold. No spam, unsubscribe in one click.
📝 Description
95
BU Score · Transcendent
About this analysis
Why low confidence: only 5 ratings · no founder-verified revenue (model estimate only) · revenue figure is directional only.
📌 Final verdict — read this before you trust the numbers above
RxCalc is a early-stage iOS app in the education space with weak public traction — only 5 ratings, no founder-verified MRR, and not ranked in any monitored grossing chart. The app appears to be monetised, but public signals are too sparse for a precise revenue estimate.
Bottom line: treat all revenue, audience and acquisition-value numbers on this page as directional only — not founder-verified facts.
❓ Frequently Asked Questions
4 answers · auto-generated from this app's public dataHow much does RxCalc make per month?▴
Low-confidence model estimate. RxCalc has only 5 App Store ratings, so our revenue model has very little signal to work with — treat the ~$18K/mo figure as directional only, not a verified MRR. No founder-verified revenue data is available for this app. See methodology for the formula and confidence bands.
What apps are like RxCalc?▴
Browse the full Education category catalog to find similar apps with revenue, build cost, audience and tech stack data. Each /p/{slug} page also shows a Compare side-by-side widget with three peer apps from the same niche.
Who makes RxCalc?▴
RxCalc is published by Rob Fahrni on the Apple App Store. See the full publisher portfolio (other apps by the same developer) via the More by developer block on the product page above.
What is RxCalc's BU Score?▴
RxCalc has a BU Score of 59/100 (Solid). The score combines App Store rating, ratings count, monetization model and revenue signals calibrated against founder-verified MRR anchors. See the BU Score formula.